Display options
Cite
Seghatchian J. What is happening? Are the current acceptance criteria for therapeutic plasma adequate?. Transfus Apher Sci. 2004;31(1):67-73doi: 10.1016/j.transci.2004.04.002.
Seghatchian, J. (2004). What is happening? Are the current acceptance criteria for therapeutic plasma adequate?. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 31(1), 67-73. https://doi.org/10.1016/j.transci.2004.04.002
Seghatchian, Jerard. "What is happening? Are the current acceptance criteria for therapeutic plasma adequate?." Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis vol. 31,1 (2004): 67-73. doi: https://doi.org/10.1016/j.transci.2004.04.002
Seghatchian J. What is happening? Are the current acceptance criteria for therapeutic plasma adequate?. Transfus Apher Sci. 2004 Aug;31(1):67-73. doi: 10.1016/j.transci.2004.04.002. PMID: 15294197.
Copy Download .nbib Format: NLM
Share it on

Transfus Apher Sci. 2004 Aug;31(1):67-73. doi: 10.1016/j.transci.2004.04.002.

What is happening? Are the current acceptance criteria for therapeutic plasma adequate?.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Jerard Seghatchian

Affiliations

  1. Blood Component Technology and Haemostasis/Thrombosis Consultant, 50 Primrose Hill Road, London NW3 3AA, UK. [email protected]

PMID: 15294197 DOI: 10.1016/j.transci.2004.04.002

Abstract

The main objective of this overview is to highlight the impact of new developments in the processing of plasma, on the quality, safety and efficacy fresh frozen plasma (FFP). Based on the currently available information, it is suggested that current guidelines need an urgent review to include more relevant criteria of acceptability for therapeutic plasma. Moreover additional streamlining of FFP production, using selective donor panel, will improve the uniformity of therapeutic plasma and lower the potential risks of transfusion reactions.

MeSH terms

Publication Types